Weekly AtriCure, Inc. (NASDAQ:ATRC) Ratings

June 29, 2018 - By Loretta Love

AtriCure, Inc. (NASDAQ:ATRC) Corporate Logo
Big Money Sentiment decreased to 0.78 in Q1 2018. It has change of 0.35, from 2017Q4’s 1.13. The ratio dropped due to AtriCure, Inc. positioning: 10 sold and 41 reduced. 14 funds amassed holdings and 26 increased holdings. Investors holded 26.90 million in 2017Q4 but now own 26.69 million shares or 0.78% less.
Solutions Limited reported 235 shs stake. Citigroup reported 4,018 shs stake. Invesco Limited accumulated 13,170 shs. State Common Retirement Fund invested 0% of its capital in AtriCure, Inc. (NASDAQ:ATRC). Jpmorgan Chase And reported 0% of its capital in AtriCure, Inc. (NASDAQ:ATRC). Kopp Advsrs Llc owns 126,846 shs. Paradigm Capital Management Ny has invested 0.19% of its capital in AtriCure, Inc. (NASDAQ:ATRC). Atlantic Tru Group Inc Limited Liability Company owns 455 shs for 0% of their capital. Tarbox Family Office reported 2,052 shs stake. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,044 shs. Prelude Cap Mngmt Limited Liability Corporation has 20,138 shs. Wellington Mgmt Ltd Liability Partnership holds 0.02% or 4.56 million shs. Geode Capital Mngmt Limited Liability Corp has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). California Pub Employees Retirement Systems has 34,600 shs for 0% of their capital. Manufacturers Life Insur The holds 0.01% or 263,831 shs in its capital.

AtriCure, Inc. registered $429,300 net activity with 2 insider buys and 5 selling transactions since February 15, 2018. Noznesky Justin J sold $68,120 worth of stock. On Monday, May 7 Krell Elizabeth D also sold $228,200 worth of AtriCure, Inc. (NASDAQ:ATRC). On Thursday, June 14 Collar Mark A had sold 2,090 shs worth $52,250. GROVES REGINA E bought 1,000 shs worth $17,430.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

In total 4 analysts cover Atricure (NASDAQ:ATRC). “Buy” rating has 3, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ATRC) has 75% bullish analysts. 11 are the (NASDAQ:ATRC)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. In Wednesday, June 27 report Canaccord Genuity maintained the stock with “Buy” rating. On Tuesday, February 27 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, June 27 the firm has “Buy” rating given by Needham. On Monday, June 18 the stock has “Buy” rating by Needham. On Wednesday, June 27 the rating was maintained by Stifel Nicolaus with “Buy”. On Friday, April 27 Stifel Nicolaus maintained the shares of ATRC in report with “Buy” rating. The stock rating was maintained by Canaccord Genuity with “Buy” on Monday, January 8. In Tuesday, February 27 report Needham maintained the stock with “Buy” rating. On Friday, April 27 the stock has “Buy” rating by Needham. On Tuesday, January 16 the stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Buy” rating by Needham. Listed here are AtriCure, Inc. (NASDAQ:ATRC) PTs and latest ratings.

27/06/2018 Broker: Canaccord Genuity Rating: Buy New Target: $35.0000 Maintain
27/06/2018 Broker: Needham Rating: Buy New Target: $32.0000 Maintain
27/06/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $23 New Target: $32 Maintain
18/06/2018 Broker: Needham Rating: Buy New Target: $32.0000 Maintain
27/04/2018 Broker: BTIG Research Rating: Hold
27/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $22 New Target: $23 Maintain
27/04/2018 Broker: Needham Rating: Buy New Target: $26.0000 Maintain
27/02/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain
27/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $26 Maintain
16/01/2018 Broker: Needham Rating: Buy New Target: $23.0 Maintain

The stock increased 0.11% or $0.03 during the last trading session, hitting $27.1.Currently AtriCure, Inc. is uptrending after 14.67% change in last June 29, 2017. ATRC has 34,783 shares volume. The stock outperformed the S&P500 by 2.10%.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally.The company has $949.58 million market cap. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.Last it reported negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

For more AtriCure, Inc. (NASDAQ:ATRC) news brought out briefly go to: Seekingalpha.com, Benzinga.com, Businesswire.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Stocks To Watch: More Trade Tiffs And Stress Tests” brought out on June 23, 2018, “25 Stocks Moving In Friday’s Pre-Market Session” on June 15, 2018, “AtriCure Announces 2018 Analyst and Investor Meeting” with a publish date: June 12, 2018, “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” and the last “Market Is Revaluing Entertainment Stocks – Cramer’s Mad Money (6/14/18)” with publication date: June 15, 2018.

AtriCure, Inc. (NASDAQ:ATRC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.